SEC Form SC 13G/A filed by Keros Therapeutics Inc. (Amendment)

2/9/24 9:16:07 AM ET

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $KROS alert in real time by email

SC 13G/A 1 filing.txt SCHEDULE 13G Amendment No.4 KEROS THERAPEUTICS INC COMMON STOCK Cusip #492327101 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [x] Rule 13d-1(b) [ ] Rule 13d-1(c) [ ] Rule 13d-1(d) Cusip #492327101 Item 1: Reporting Person - FMR LLC Item 2: (a) [ ] (b) [ ] Item 4: Delaware Item 5: 3,873,924 Item 6: 0 Item 7: 3,874,204 Item 8: 0 Item 9: 3,874,204 Item 11: 12.931% Item 12: HC Cusip #492327101 Item 1: Reporting Person - Abigail P. Johnson Item 2: (a) [ ] (b) [ ] Item 4: United States of America Item 5: 0 Item 6: 0 Item 7: 3,874,204 Item 8: 0 Item 9: 3,874,204 Item 11: 12.931% Item 12: IN Item 1(a). Name of Issuer: KEROS THERAPEUTICS INC Item 1(b). Address of Issuer's Principal Executive Offices: 1050 WALTHAM STREET, SUITE 302 Lexington, MA 02421 USA Item 2(a). Name of Person Filing: FMR LLC Item 2(b). Address or Principal Business Office or, if None, Residence: 245 Summer Street, Boston, Massachusetts 02210 Item 2(c). Citizenship: Not applicable Item 2(d). Title of Class of Securities: COMMON STOCK Item 2(e). CUSIP Number: 492327101 Item 3. This statement is filed pursuant to Rule 13d-1(b) or 13d-2(b) or (c) and the person filing, FMR LLC, is a parent holding company in accordance with Section 240.13d-1(b)(1)(ii)(G). (Note: See Exhibit A). Item 4. Ownership (a) Amount Beneficially Owned: 3,874,204 (b) Percent of Class: 12.931% (c) Number of shares as to which such person has: (i) sole power to vote or to direct the vote: Please see the responses to Items 5 and 6 on the cover page (ii) shared power to vote or to direct the vote: 0 (iii) sole power to dispose or to direct the disposition of: 3,874,204 (iv) shared power to dispose or to direct the disposition of: 0 Item 5. Ownership of Five Percent or Less of a Class. Not applicable. Item 6. Ownership of More than Five Percent on Behalf of Another Person. One or more other persons are known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the COMMON STOCK of KEROS THERAPEUTICS INC. No one other person's interest in the COMMON STOCK of KEROS THERAPEUTICS INC is more than five percent of the total outstanding COMMON STOCK. Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company. See attached Exhibit A. Item 8. Identification and Classification of Members of the Group. Not applicable. Item 9. Notice of Dissolution of Group. Not applicable. Item 10. Certifications. By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect. Signature After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. February 8, 2024 Date /s/ Stephanie J. Brown Signature Stephanie J. Brown Duly authorized under Power of Attorney effective as of January 3, 2023, by and on behalf of FMR LLC and its direct and indirect subsidiaries* * This power of attorney is incorporated herein by reference to Exhibit 24 to the Schedule 13G filed by FMR LLC on January 10, 2023, accession number: 0000315066-23-000003. Exhibit A Pursuant to the instructions in Item 7 of Schedule 13G, the following table lists the identity and Item 3 classification, if applicable, of each relevant entity that beneficially owns shares of the security class being reported on this Schedule 13G. Entity ITEM 3 Classification FIAM LLC IA Fidelity Institutional Asset Management Trust Company BK Fidelity Management & Research Company LLC * IA * Entity beneficially owns 5% or greater of the outstanding shares of the security class being reported on this Schedule 13G. Abigail P. Johnson is a Director, the Chairman and the Chief Executive Officer of FMR LLC. Members of the Johnson family, including Abigail P. Johnson, are the predominant owners, directly or through trusts, of Series B voting common shares of FMR LLC, representing 49% of the voting power of FMR LLC. The Johnson family group and all other Series B shareholders have entered into a shareholders' voting agreement under which all Series B voting common shares will be voted in accordance with the majority vote of Series B voting common shares. Accordingly, through their ownership of voting common shares and the execution of the shareholders' voting agreement, members of the Johnson family may be deemed, under the Investment Company Act of 1940, to form a controlling group with respect to FMR LLC. This filing reflects the securities beneficially owned, or that may be deemed to be beneficially owned, by FMR LLC, certain of its subsidiaries and affiliates, and other companies (collectively, the "FMR Reporters"). This filing does not reflect securities, if any, beneficially owned by certain other companies whose beneficial ownership of securities is disaggregated from that of the FMR Reporters in accordance with Securities and Exchange Commission Release No. 34-39538 (January 12, 1998). RULE 13d-1(k)(1) AGREEMENT The undersigned persons, on February 8, 2024, agree and consent to the joint filing on their behalf of this Schedule 13G in connection with their beneficial ownership of the COMMON STOCK of KEROS THERAPEUTICS INC at December 29, 2023. FMR LLC By /s/ Stephanie J. Brown Stephanie J. Brown Duly authorized under Power of Attorney effective as of January 3, 2023, by and on behalf of FMR LLC and its direct and indirect subsidiaries* Abigail P. Johnson By /s/ Stephanie J. Brown Stephanie J. Brown Duly authorized under Power of Attorney effective as of January 26, 2023, by and on behalf of Abigail P. Johnson** * This power of attorney is incorporated herein by reference to Exhibit 24 to the Schedule 13G filed by FMR LLC on January 10, 2023, accession number: 0000315066-23-000003. ** This power of attorney is incorporated herein by reference to Exhibit 24 to the Schedule 13G filed by FMR LLC on January 31, 2023, accession number: 0000315066-23-000038.

Get the next $KROS alert in real time by email

Recent Analyst Ratings for

$KROS

Date	Price Target	Rating	Analyst
6/10/2025	$18.00	Buy → Neutral	BofA Securities
1/21/2025		Overweight → Neutral	Cantor Fitzgerald
1/17/2025	$15.00	Outperform → Neutral	Wedbush
12/16/2024	$102.00 → $63.00	Outperform	Oppenheimer
12/16/2024		Buy → Neutral	Guggenheim
12/13/2024	$100.00 → $47.00	Buy	H.C. Wainwright
12/12/2024		Buy → Hold	TD Cowen
12/12/2024		Outperform → Mkt Perform	William Blair

More analyst ratings

SEC Form SC 13G/A filed by Keros Therapeutics Inc. (Amendment)

2/9/24 9:16:07 AM ET

$KROS

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $KROS alert in real time by email

Recent Analyst Ratings for

$KROS

Date	Price Target	Rating	Analyst
6/10/2025	$18.00	Buy → Neutral	BofA Securities
1/21/2025		Overweight → Neutral	Cantor Fitzgerald
1/17/2025	$15.00	Outperform → Neutral	Wedbush
12/16/2024	$102.00 → $63.00	Outperform	Oppenheimer
12/16/2024		Buy → Neutral	Guggenheim
12/13/2024	$100.00 → $47.00	Buy	H.C. Wainwright
12/12/2024		Buy → Hold	TD Cowen
12/12/2024		Outperform → Mkt Perform	William Blair

More analyst ratings

SEC Form SC 13G/A filed by Keros Therapeutics Inc. (Amendment)

Crush Q3 2025 with the Best AI Superconnector

Recent Analyst Ratings for
$KROS

SEC Form SC 13G/A filed by Keros Therapeutics Inc. (Amendment)

Crush Q3 2025 with the Best AI Superconnector

Recent Analyst Ratings for
$KROS

$KROS
Press Releases

Keros Therapeutics Presents Additional Clinical Data from its KER-065 Program at the American Society of Bone and Mineral Research 2025 Annual Meeting

Keros Therapeutics Announces Participation at Upcoming Healthcare Conferences

ADAR1 Sends Open Letter to Keros Board of Directors Urging the Board to Engage Constructively on Strategy, Capital Allocation and Board Refreshment

$KROS
Insider Trading

CHIEF EXECUTIVE OFFICER Seehra Jasbir was granted 90,500 shares, increasing direct ownership by 30% to 392,723 units (SEC Form 4)

New insider Lerner Lorena Raquel claimed ownership of 35,000 shares (SEC Form 3)

New insider Cho Esther claimed ownership of 44,000 shares (SEC Form 3)

$KROS
SEC Filings

Keros Therapeutics Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

Keros Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

Keros Therapeutics Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

$KROS
Insider Purchases

Large owner Adar1 Capital Management, Llc bought $328,127 worth of shares (34,925 units at $9.40) (SEC Form 4)

$KROS
Analyst Ratings

Keros Therapeutics downgraded by BofA Securities with a new price target

Keros Therapeutics downgraded by Cantor Fitzgerald

Keros Therapeutics downgraded by Wedbush with a new price target

$KROS
Leadership Updates

Keros Therapeutics Appoints Yung H. Chyung, M.D., as Chief Medical Officer

Keros Therapeutics Appoints Jean-Jacques Bienaimé to its Board of Directors

Keros Therapeutics Appoints Alpna Seth, Ph.D., to its Board of Directors

$KROS
Financials

ADAR1 Sends Open Letter to Keros Board of Directors Urging the Board to Engage Constructively on Strategy, Capital Allocation and Board Refreshment

Keros to Exclusively Prioritize the Clinical Advancement of KER-065

Keros Therapeutics Reports Second Quarter 2025 Financial Results

$KROS
Large Ownership Changes